Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MIST |
---|---|---|
09:32 ET | 1090 | 1.57 |
09:34 ET | 2343 | 1.5959 |
09:39 ET | 500 | 1.5534 |
09:41 ET | 8453 | 1.6166 |
10:03 ET | 100 | 1.58 |
10:10 ET | 100 | 1.6 |
10:15 ET | 220 | 1.59 |
10:24 ET | 100 | 1.6 |
10:32 ET | 500 | 1.6 |
10:42 ET | 6750 | 1.6 |
10:50 ET | 1300 | 1.6 |
10:51 ET | 225 | 1.5902 |
11:02 ET | 100 | 1.6247 |
11:11 ET | 100 | 1.63 |
11:38 ET | 2318 | 1.61 |
11:58 ET | 3368 | 1.6 |
12:05 ET | 2600 | 1.58 |
12:09 ET | 100 | 1.6 |
12:18 ET | 5800 | 1.58 |
12:20 ET | 100 | 1.585 |
12:45 ET | 983 | 1.5707 |
01:14 ET | 3032 | 1.63 |
01:17 ET | 12400 | 1.6 |
01:19 ET | 5000 | 1.595 |
01:21 ET | 100 | 1.599 |
01:32 ET | 909 | 1.59 |
01:35 ET | 977 | 1.5812 |
01:39 ET | 1000 | 1.59 |
01:48 ET | 300 | 1.59 |
01:50 ET | 100 | 1.59 |
01:53 ET | 2000 | 1.5891 |
01:57 ET | 600 | 1.59 |
02:00 ET | 200 | 1.59 |
02:09 ET | 250 | 1.58 |
02:11 ET | 1000 | 1.5899 |
02:13 ET | 100 | 1.585 |
02:20 ET | 200 | 1.59 |
02:22 ET | 100 | 1.59 |
02:24 ET | 200 | 1.59 |
02:26 ET | 500 | 1.58 |
02:29 ET | 100 | 1.59 |
02:38 ET | 1886 | 1.5873 |
02:51 ET | 400 | 1.59 |
02:54 ET | 200 | 1.59 |
03:09 ET | 1636 | 1.58 |
03:12 ET | 100 | 1.59 |
03:38 ET | 100 | 1.59 |
03:39 ET | 2050 | 1.59 |
03:41 ET | 100 | 1.59 |
03:54 ET | 500 | 1.59 |
03:56 ET | 3340 | 1.57 |
03:57 ET | 54700 | 1.54 |
03:59 ET | 1939 | 1.57 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Milestone Pharmaceuticals Inc | 83.4M | -1.1x | --- |
Provectus Biopharmaceuticals Inc | 83.5M | -26.9x | --- |
Chimerix Inc | 83.4M | -1.0x | --- |
Beyondspring Inc | 86.4M | -3.2x | --- |
BioXcel Therapeutics Inc | 86.3M | -0.4x | --- |
Aileron Therapeutics Inc | 83.5M | -1.5x | --- |
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $83.4M |
---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 53.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.79 |
EPS | $-1.39 |
Book Value | $0.50 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 83.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,109.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.